New antibiotic shows promise for treating MRSA pneumonia

September 11, 2013

A drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia, according to a Henry Ford Hospital study.

Researchers found that patients treated with the antibiotic ceftaroline fosamil, or CPT-F, had a lower mortality rate after 28 days than the mortality rate seen in patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.

In the , 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three were attributed to other serious medical conditions.

The mortality rate for patients treated with vancomycin has been reported to be as high as 32 percent after 28 days. In the Henry Ford study, the mortality rate for the CPT-F treated population was 13 percent.

The study is being presented Wednesday at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver.

"Many things fall under the umbrella of proper and appropriate MRSA pneumonia treatment, and these results present a possible benefit with the use of CPT-F," says Samia Arshad, a Henry Ford Infectious Diseases epidemiologist and the study's lead author. "It is critical for us to find alternative drug therapies to improve patient outcomes. Further research is needed to test the efficacy of CPT-F on a larger patient population as CPT-F offers doctors another viable option for treating patients with MRSA pneumonia."

In 2010 the U.S. Food and Drug Administration approved CPT-F, an injectable antibiotic, for treating patients with bacterial infections like community-acquired and . Henry Ford's study is the first to evaluate the efficacy of MRSA treated with CPT-F. MRSA pneumonia is highly antibiotic resistant and most common in patients 65 years or older.

Researchers evaluated 38 patients treated with CPT-F. Twenty of these patients were failing standard treatment with either and/or cefepime, and were switched to CPT-F. Researchers say no complications were reported in those 20 patients.

Researchers will continue to look for other patients treated with CPT-F for MRSA pneumonia, and will match these patients to others treated with different antibiotics to conduct a matched cohort analysis.

Explore further: Study: Optimal treatment duration for MRSA-related pneumonia

More information: The study was funded by Forest Laboratories, Inc.

Related Stories

Study: Optimal treatment duration for MRSA-related pneumonia

October 19, 2012
The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

Vibativ approved for certain bacterial pneumonia

June 24, 2013
(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Antibiotic linezolid an effective option for treating patients with MRSA infection

May 16, 2011
The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.